Genovis (GENO) Q1 2026 earnings summary

Executive summary

• Net sales reached SEK 33,506 thousand, up 4% year-over-year, or 17% when adjusted for currency effects.

• EBITDA improved to SEK 9,510 thousand, with a margin of 28.4%, reflecting strong cost discipline.

• Cash flow from operating activities was robust at SEK 16,511 thousand, reinforcing financial flexibility.

• Product launches and strategic partnerships expanded the offering in genomics and ADC technologies.

• Large pharma segment saw organic growth exceeding 30%, while biotech showed sequential recovery.

Financial highlights

• Net sales: SEK 33,506 thousand (SEK 32,292 thousand Q1 2025), 4% reported growth, 17% currency-adjusted.

• EBITDA: SEK 9,510 thousand (SEK 8,906 thousand), margin 28.4% (27.6%).

• EBIT: SEK 5,777 thousand (SEK 6,391 thousand), margin 17.2% (19.8%).

• Earnings per share: SEK 0.06 (SEK 0.05).

• Cash flow from operating activities: SEK 16,511 thousand (SEK 10,652 thousand).

Outlook and guidance

• Business opportunities and operational capacity assessed as good for 2026, despite macroeconomic and geopolitical uncertainties.

• Continued advances expected in new product launches and sales.